Online inquiry

IVTScrip™ mRNA-Anti-CFD, AFD Anti-fD(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ1820MR)

This product GTTS-WQ1820MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets CFD gene. The antibody can be applied in Age-related macular degeneration (AMD) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001317335.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1675
UniProt ID P00746
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CFD, AFD Anti-fD(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ1820MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2286MR IVTScrip™ mRNA-Anti-C5, ALXN1007(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA ALXN1007
GTTS-WQ5029MR IVTScrip™ mRNA-Anti-GLP1R, CA Exendin-4(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CA Exendin-4
GTTS-WQ13919MR IVTScrip™ mRNA-Anti-INHBA, REGN2477(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA REGN2477
GTTS-WQ5705MR IVTScrip™ mRNA-Anti-CD3E&CEACAM5, CEA TCB(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CEA TCB
GTTS-WQ11074MR IVTScrip™ mRNA-Anti-EGFR&LGR5, MCLA-158(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MCLA-158
GTTS-WQ14696MR IVTScrip™ mRNA-Anti-MS4A1, SCT-400(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA SCT-400
GTTS-WQ12366MR IVTScrip™ mRNA-Anti-EGFR, N63Ab(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA N63Ab
GTTS-WQ10626MR IVTScrip™ mRNA-Anti-MAPT, LY-3303560(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA LY-3303560
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW